NewcelX Ltd. Annual Report - How They Did This Year

I’ve put together this guide to help you understand NewcelX Ltd.’s latest annual report. My goal is to cut through the corporate jargon and explain how the company is performing, whether it’s a sound investment, and what you should watch.

1. The Big Picture

NewcelX is a clinical-stage pharmaceutical company. They focus on "off-the-shelf" cell therapies—lab-grown cells designed to treat diseases. Because they are in the research phase, they do not yet have products to sell to the public.

In October 2025, the company merged with an Israeli firm, Kadimastem. Following this merger, they rebranded from "NLS Pharmaceutics" to "NewcelX Ltd." This move combines Kadimastem’s technology with the existing research infrastructure of the former NLS Pharmaceutics to create a unified pipeline of potential treatments.

2. The Money Talk

Since the company is not yet generating sales, their financial health is entirely dependent on their cash reserves.

The company has reported that their current cash on hand is insufficient to cover their planned operations for the next 12 months. This creates a "going concern" status, meaning the company must secure additional funding—through selling more shares, taking on debt, or forming new partnerships—to continue their research programs.

3. Highs and Lows

• The Merger: The combination with Kadimastem is the primary driver of the company’s current strategy. By pooling their intellectual property and research platforms, they aim to accelerate the development of their cell therapy pipeline.
• The Share Split: The company executed a "1-for-10 reverse share split." This action was taken to reduce the number of shares in circulation, which helps boost the share price to meet stock exchange listing requirements.

4. Financial Health

NewcelX operates as an "emerging growth company." This classification allows them to utilize simplified financial reporting, such as skipping detailed audits of internal financial controls and delaying the adoption of certain accounting standards. Their financial statements reflect a business model that relies exclusively on external capital to fund administrative and research-related expenses.

5. Risks to Consider

• Dilution Risk: Because the company needs to raise more money to survive, they will likely issue and sell more shares. This would reduce the ownership percentage of existing shareholders.
• Development Risk: The company’s value is tied entirely to the success of its clinical trials. If these trials fail or if regulators do not approve their data, the company has no alternative revenue streams to fall back on.
• Geopolitical Risk: With a significant portion of operations now based in Israel, the company faces potential disruptions to its research facilities, logistics, and staff due to regional instability.

6. What’s Next

The company is currently focused on integrating their teams and advancing their cell therapy trials. If you are considering an investment, the most important things to watch are announcements regarding new funding and updates from their clinical trials. These two factors will be the primary drivers of the company’s future value and its ability to remain in operation.